CorMedix (CRMD) Cash & Equivalents (2010 - 2025)

CorMedix (CRMD) has 16 years of Cash & Equivalents data on file, last reported at $144.8 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 256.29% year-over-year to $144.8 million; the trailing twelve-month figure through Dec 2025 stood at $144.8 million (up 256.29% YoY), and the FY2025 full-year result was $144.8 million, up 256.29% from the prior year.
• Cash & Equivalents grew to $144.8 million in Q4 2025, from $48.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $159.3 million in Q2 2025 to a low of $19.7 million in Q2 2023.
• A 5-year average of $52.9 million and a median of $43.2 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents jumped 44315.93% in 2021 and sank 70.38% in 2022, its largest moves.
• Tracing CRMD's Cash & Equivalents over 5 years: stood at $53.3 million in 2021, then slipped by 19.07% to $43.1 million in 2022, then gained by 1.15% to $43.6 million in 2023, then fell by 6.85% to $40.7 million in 2024, then jumped by 256.29% to $144.8 million in 2025.
• Business Quant data shows CRMD's Cash & Equivalents at $144.8 million in Q4 2025, $48.5 million in Q3 2025, and $159.3 million in Q2 2025.